UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products
July 15, 2013 at 08:55 AM EDT
In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio (NASDAQ: BLUE ) with an Overweight rating and a $44 price target. In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our
